This report provides comprehensive information on the therapeutic development for Tularaemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tularaemia and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Tularaemia Overview
- Therapeutics Development
- Pipeline Products for Tularaemia - Overview
- Pipeline Products for Tularaemia - Comparative Analysis
- Tularaemia - Therapeutics under Development by Companies
- Tularaemia - Therapeutics under Investigation by Universities/Institutes
- Tularaemia Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Tularaemia - Products under Development by Companies
- Tularaemia - Products under Investigation by Universities/Institutes
- Tularaemia - Companies Involved in Therapeutics Development
- Aradigm Corporation
- Arno Therapeutics, Inc.
- DynPort Vaccine Company LLC
- Emergent BioSolutions Inc.
- EpiVax, Inc.
- Grifols, S.A.
- Merck & Co., Inc.
- Tetraphase Pharmaceuticals Inc.
For more information visit http://www.researchandmarkets.com/research/bk4nh3/tularaemia